<DOC>
	<DOCNO>NCT02024659</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled clinical trial enrol subject eosinophilic CRSwNP . Subjects randomize receive either budesonide inhalation suspension placebo 14 day . Visual analogue scale ( VAS）of nasal symptom , endoscopic polyp score morning serum cortical level assess pre- post-treatment . Polyp sample evaluate inflammatory cytokine , matrix metalloproteinases ( MMPs ) tissue inhibitor metalloproteinases ( TIMPs ) immunoassay ; collagen histochemistry ; frequency different inflammatory T cell infiltration flow cytometry . study undertaken evaluate efficacy short-term prescription budesonide inhalation suspension via transnasal nebulization clinical immunologic assessment . As outcome parameter remodel , difference expression collagen albumin investigate budesonide treatment . Meanwhile , TGF-β , MMPs TIMPs expression difference nasal polyp investigate explore underlying mechanism tissue reconstitution .</brief_summary>
	<brief_title>Effects Safety Budesonide Inhalation Suspension Via Transnasal Nebulization Nasal Polyps</brief_title>
	<detailed_description />
	<mesh_term>Polyps</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Diagnosis chronic rhinosinusitis make basis symptom rhinosinusitis least 12 week , confirm abnormality sinus compute tomography scan . Bilateral nasal polyp present . CRSwNP define eosinophilic percent tissue eosinophils exceed 10 % total infiltrating cell . All patient take steroid antibiotic least 4 week sample collection . cystic fibrosis pregnancy serious unstable concurrent disease psychological disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>nasal polyp</keyword>
	<keyword>remodel</keyword>
	<keyword>inflammatory cell</keyword>
	<keyword>budesonide</keyword>
</DOC>